SNZZF OTC

Based in Uppsala, Sweden, Senzime AB (publ) is a medical technology company founded in 1999, specializing in the development and commercialization of advanced patient monitoring systems. These systems are designed to oversee individuals under anesthesia across a wide geographic reach, including Europe, Oceania, Asia, Canada, and the United States. A key offering is the TetraGraph monitor, which precisely stimulates, measures, analyzes, and displays muscle function for surgical patients administered neuromuscular blocking agents. The system includes the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. Its TetraConnect data management portal allows clinicians to easily access, view, and export records from the TetraGraph in PDF or Excel format. Additionally, TetraGraph Device Connectivity facilitates the transfer of data from the monitor to other patient monitoring systems. A specific TetraGraph Philips Interface enables the direct transmission of neuromuscular monitoring parameters (TOFC, TOFR, PTC, and TOF bars) to Philips patient monitors, displaying readings on the Philips Intellivue Monitor. The company's portfolio also includes the CliniSenz Analyzer, developed for continuous postoperative patient surveillance in hospital settings. Furthermore, the Onzurf Probe is a sterile, CE-marked, single-use micro-dialysis product that allows for continuous sampling from gastrointestinal organs like the esophagus, stomach, and liver. Senzime AB (publ) has entered into a strategic license and connectivity agreement with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to connect directly with Masimo's Root monitoring system and its digital hubs for seamless integration with hospital clinical information systems and electronic health records.